Docetaxel kullanımına bağlı bir palmoplanter eritrodizestezi sendromu olgusu

Amaç: Sistemik kemoterapi ilaçları bazen özel bir kutanöz ilaç reaksiyonu olan palmoplanter eritrodistezi sendromuna yol açabilmektedir. Özellikle 5-Flourourasil, doksorubisin ve sitozin arabinosidler bu tablodan sorumludur. Olgu sunumu: Burada memenin invazif lobüler duktal karsinomu nedeniyle tedavi gören kırk beş yaşında bir kadın hastada docetaxel tedavisini takiben gelişen palmoplanter eritrodizestezi sendromu sunulmaktadır. Sonuç: Palmoplanter eritrodizestezi sendromu yeni ilaç tedavileri ile daha sık görülebilir. Bu nedenle, klinisyenler tarafından daha iyi tanınması yararlı olacaktır.

A case of palmoplantar erythrodysesthesıa syndrome caused by docetaxel

Objective: Systemic chemotherapeutics could cause palmoplanter erythrodysesthesia syndrome which is a special type of cutaneous drug reaction. Especially 5-Fluorouracil, doxorubicine and cytosoid arabinosoids are responsible for this syndrome. Case report: We present a 45-years-old female patient with palmoplantar erythrodysesthesia syndrome after receiving docetaxel due to invasive ductal carcinoma of breast. Conclusion: Palmoplanter erythrodysestesia syndrome could be seen more frequently with new drug therapies. Therefore, it should be useful to better recognition by the clinicians.

PDF

___

1. Bastida J, Diaz-Cascajo C, Borghi S. Chemotherapy-induced acral erythema due to Tegafur. Acta Derm Venereol 1997;77:72–3.
2. Waltzer JF, Flowers FP. Bullous variant of chemotherapyinduced acral erythema. Arch Dermatol 1993; 129: 43–5.
3. Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131: 202–6.
4. Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000; 142: 808–11.
5. James WD, Berger TG, Elston DM. Andrews’ Diseases of the Skin: Clinical Dermatology. 10th edn. Philadelphia: W.B. Saunders Company; 2006, p:132.
6. Schrijvers D, van den Brande J, Vermorken J. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 2000; 142: 1069–70.
7. Susser W, Whitaker-Worth D, Grant-Kels J. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367–98.
8. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24: 457–61.
9. Schrijvers D, Wanders J, Dirix L. Coping with toxicities of docetaxel. Ann Oncol 1993; 4: 610–1.
10. Komamura H, Higashiyama M, Hashimoto K, Takeda K, Kimura. H, Tani Y, et al. Three cases of chemotherapyinduced acral erythema, J Dermatol 1995; 22:116–21.
11. Hueso L, Sanmartín O, Nagore E, Botella-Estrada R, Requena C, Llombart B, et al. Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases. Actas Dermosifiliogr 2008;99:281-90.
12. Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006 Sep-Oct;16(5):494-9.
13. Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006; 15: 414-24.